Drugstars ApS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
Loading...

Loading...

Loading...

Loading...

Loading...

Loading...

Loading...

Bankruptcy Risk 
2016
2016/12
2017
2017/12
2018
N/A
2019
2019/12
2020
2020/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  8.2% 9.8% 0.0% 12.3% 18.7%  
Credit score (0-100)  32 27 0 20 7  
Credit rating  BB BB N/A BB B  
Credit limit (kDKK)  0.0 0.0 0.0 0.0 -0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2016
2016/12
2017
2017/12
2018
N/A
2019
2019/12
2020
2020/12

Net sales  0 0 0 1,061 1,634  
Gross profit  -963 -1,940 0.0 -4,397 -2,069  
EBITDA  -1,191 -3,744 0.0 -9,067 -7,534  
EBIT  -1,191 -3,744 0.0 -9,086 -7,564  
Pre-tax profit (PTP)  -1,191.3 -3,745.7 0.0 -9,163.0 -7,730.1  
Net earnings  -944.0 -3,302.4 0.0 -8,330.1 -6,950.4  
Pre-tax profit without non-rec. items  -1,191 -3,746 0.0 -9,163 -7,730  

 
See the entire income statement

Balance sheet (kDKK) 
2016
2016/12
2017
2017/12
2018
N/A
2019
2019/12
2020
2020/12

Tangible assets total  0.0 0.0 0.0 101 70.7  
Shareholders equity total  1,282 2,875 0.0 6,591 -359  
Interest-bearing liabilities  15.0 15.4 0.0 0.0 2,479  
Balance sheet total (assets)  1,490 3,203 0.0 8,980 5,246  

Net Debt  -1,082 -2,452 0.0 -7,487 -725  
 
See the entire balance sheet

Volume 
2016
2016/12
2017
2017/12
2018
N/A
2019
2019/12
2020
2020/12

Net sales  0 0 0 1,061 1,634  
Net sales growth  0.0% 0.0% 0.0% 0.0% 53.9%  
Gross profit  -963 -1,940 0.0 -4,397 -2,069  
Gross profit growth  0.0% -101.4% 0.0% 0.0% 52.9%  
Employees  1 4 0 8 9  
Employee growth %  0.0% 300.0% -100.0% 0.0% 12.5%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  1,490 3,203 0 8,980 5,246  
Balance sheet change%  0.0% 114.9% -100.0% 0.0% -41.6%  
Added value  -1,191.2 -3,744.0 0.0 -9,086.4 -7,533.7  
Added value %  0.0% 0.0% 0.0% -856.2% -461.2%  
Investments  0 0 0 81 -60  

Net sales trend  0.0 0.0 0.0 0.0 1.0  
EBIT trend  -1.0 -2.0 0.0 -1.0 -2.0  

Profitability 
2016
2016/12
2017
2017/12
2018
N/A
2019
2019/12
2020
2020/12
EBITDA %  0.0% 0.0% 0.0% -854.3% -461.2%  
EBIT %  0.0% 0.0% 0.0% -856.2% -463.0%  
EBIT to gross profit (%)  123.7% 193.0% 0.0% 206.7% 365.6%  
Net Earnings %  0.0% 0.0% 0.0% -784.9% -425.5%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% -783.1% -423.6%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% -863.4% -473.2%  
ROA %  -79.9% -159.6% 0.0% -101.2% -103.7%  
ROI %  -91.9% -178.8% 0.0% -137.8% -166.8%  
ROE %  -73.7% -158.9% 0.0% -126.4% -117.4%  

Solidity 
2016
2016/12
2017
2017/12
2018
N/A
2019
2019/12
2020
2020/12
Equity ratio %  86.0% 89.8% 0.0% 73.4% -6.4%  
Relative indebtedness %  0.0% 0.0% 0.0% 225.0% 343.1%  
Relative net indebtedness %  0.0% 0.0% 0.0% -480.4% 147.0%  
Net int. bear. debt to EBITDA, %  90.8% 65.5% 0.0% 82.6% 9.6%  
Gearing %  1.2% 0.5% 0.0% 0.0% -690.6%  
Net interest  0 0 0 0 0  
Financing costs %  3.2% 13.1% 0.0% 0.0% 13.5%  

Liquidity 
2016
2016/12
2017
2017/12
2018
N/A
2019
2019/12
2020
2020/12
Quick Ratio  7.6 10.1 0.0 3.7 1.7  
Current Ratio  7.6 10.1 0.0 3.7 1.7  
Cash and cash equivalent  1,097.1 2,467.7 0.0 7,486.9 3,203.8  

Capital use efficiency 
2016
2016/12
2017
2017/12
2018
N/A
2019
2019/12
2020
2020/12
Trade debtors turnover (days)  0.0 0.0 0.0 171.5 233.3  
Trade creditors turnover (days)  0.0 0.0 0.0 4.6 6.4  
Current assets / Net sales %  0.0% 0.0% 0.0% 836.6% 316.8%  
Net working capital  1,266.7 2,853.1 0.0 6,490.8 2,049.2  
Net working capital %  0.0% 0.0% 0.0% 611.6% 125.4%  

Employee efficiency 
2016
2016/12
2017
2017/12
2018
N/A
2019
2019/12
2020
2020/12
Net sales / employee  0 0 0 133 182  
Added value / employee  -1,191 -936 0 -1,136 -837  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  -1,191 -936 0 -1,133 -837  
EBIT / employee  -1,191 -936 0 -1,136 -840  
Net earnings / employee  -944 -826 0 -1,041 -772